Tim Wilsdon

Charles River Associates
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Quantifying public and private investment in biopharmaceutical R&D: a study of seven middle- and high-income countries.

Quantifying public and private investment in biopharmaceutical R&D: a study of seven middle- and high-income countries.

Journal: Journal of pharmaceutical policy and practice

Published: April 27, 2026

From aspiration to reality: a cross-country analysis of the implementation of lung cancer screening in Europe.

From aspiration to reality: a cross-country analysis of the implementation of lung cancer screening in Europe.

Journal: Frontiers in public health

Published: December 12, 2025

Optimising Investment in Health Innovations in Europe.

Optimising Investment in Health Innovations in Europe.

Journal: Journal of market access & health policy

Published: November 18, 2025

Correction: The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies.

Correction: The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies.

Journal: Frontiers in pharmacology

Published: August 26, 2025

Policy solutions to improve access to fertility treatment and optimise patient care: consensus from an expert forum.

Policy solutions to improve access to fertility treatment and optimise patient care: consensus from an expert forum.

Journal: Frontiers in reproductive health

Published: April 08, 2025

The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies.

The unexploited potential of data systems tracking medicines utilization: an opportunity to improve access to oncology combination therapies.

Journal: Frontiers in pharmacology

Published: November 21, 2024

Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay?

Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay?

Journal: Journal of market access & health policy

Published: October 11, 2024

Quantifying public and private investment in European biopharmaceutical research and development.

Quantifying public and private investment in European biopharmaceutical research and development.

Journal: Health affairs scholar

Published: December 03, 2023

Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review.

Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review.

Journal: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Published: November 20, 2023

Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption.

Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption.

Journal: Frontiers in public health

Published: July 20, 2023

An international comparative analysis and roadmap to sustainable biosimilar markets.

An international comparative analysis and roadmap to sustainable biosimilar markets.

Journal: Frontiers in pharmacology

Published: March 17, 2023

A review of the sustainability of vaccine funding across Europe and implications for post-COVID policymaking.

A review of the sustainability of vaccine funding across Europe and implications for post-COVID policymaking.

Journal: Health policy (Amsterdam, Netherlands)

Published: March 28, 2022

Showing 1-12 of 16

Last Updated: 09/26/2026